TNFRSF1A and neoplasm: Future in vivo studies must now show whether αCD40 and α41BB fusion proteins with a PDL1 blocking anchoring domain are superior with respect to anti-tumor efficacy and side effects compared to the combined application of PDL1 blocking antibodies and conventional CD40- and 41BB-specific antibodies triggering TNFR- and FcγR signaling.